TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 168 filers reported holding TRAVERE THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is 1.97 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $113,576 | +1239.2% | 13,817 | +1156.1% | 0.00% | – |
| Q1 2024 | $8,481 | -84.4% | 1,100 | -81.8% | 0.00% | -100.0% |
| Q4 2023 | $54,237 | -23.5% | 6,033 | -23.9% | 0.00% | -50.0% |
| Q3 2023 | $70,886 | -23.8% | 7,929 | +31.0% | 0.00% | -33.3% |
| Q2 2023 | $92,974 | +130849.3% | 6,053 | +92.8% | 0.00% | +50.0% |
| Q1 2023 | $71 | -36.6% | 3,139 | -41.2% | 0.00% | -60.0% |
| Q4 2022 | $112 | -99.9% | 5,336 | -34.1% | 0.01% | +66.7% |
| Q3 2022 | $199,000 | -58.6% | 8,099 | -59.2% | 0.00% | -72.7% |
| Q2 2022 | $481,000 | +74.9% | 19,861 | +85.8% | 0.01% | +266.7% |
| Q1 2022 | $275,000 | +21.7% | 10,690 | +46.4% | 0.00% | -25.0% |
| Q4 2021 | $226,000 | +69.9% | 7,301 | +33.3% | 0.00% | +33.3% |
| Q3 2021 | $133,000 | +84.7% | 5,479 | +10.6% | 0.00% | +50.0% |
| Q2 2021 | $72,000 | +22.0% | 4,956 | +110.9% | 0.00% | +100.0% |
| Q1 2021 | $59,000 | +40.5% | 2,350 | +51.5% | 0.00% | 0.0% |
| Q4 2020 | $42,000 | – | 1,551 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |